Balanced news tone
News Sentiment
ANL sentiment intelligence
Adlai Nortye Ltd. American Depositary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Weighted score
56
Balanced news tone
52 relevant articles
Price is moving more forcefully than the current news tone suggests.
78/100 classification confidence.
directly relevant articles
high-authority source matches
+4.0% over one week, -4.4% over four weeks, trend active, and materially above fair value.
Enterprise value to EBITDA forward of Adlai Nortye Ltd. – NASDAQ:ANL
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Primary event
Market update
78/100 classification
One-week reaction
4.0%
Price confirming higher
Trend fit
Trend active
-4.4% over four weeks
Fair value
82.3%
Materially above fair value
Sentiment Mix
Positive, neutral, negative
Positive
16
Neutral
32
Negative
4
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
Above 50
Neutral zone
Below 50
News Tape
Relevant headlines
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Adlai Nortye Ltd. – NASDAQ:ANL
This article presents the enterprise value to EBITDA forward for Adlai Nortye Ltd. (NASDAQ: ANL). The content focuses on financial data for the company, accessible through TradingView, and provides no textual analysis or commentary beyond the headline and basic informational stru
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 15 Jul 2026 00:44
- Source
- TradingView
GlobeNewswire
Direct company coverage
Adlai Nortye Expands Scientific Advisory Board with Appointment of Two Leading Medical Oncologists
Adlai Nortye Ltd., a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing two prominent medical oncologists, Dr. David S. Hong and Dr. Piro Lito. This strategic move aims to leverage their expertise in clinical development, translational
- Tone
- Positive 72/100
- Event
- Balance sheet
- Published
- 14 Jul 2026 01:41
- Source
- GlobeNewswire
Investing.com
Direct company coverage
Adlai Nortye expands scientific advisory board with two oncologists
Adlai Nortye Ltd. (NASDAQ:ANL) has appointed two leading medical oncologists, Dr. David S. Hong and Dr. Piro Lito, to its Scientific Advisory Board, enhancing its focus on RAS-targeted cancer therapies. The clinical-stage biotechnology company, despite a recent 9.6% stock decline
- Tone
- Positive 67/100
- Event
- Market update
- Published
- 14 Jul 2026 01:41
- Source
- Investing.com
Moomoo
Direct company coverage
Press Release: Adlai Nortye Expands Scientific Advisory Board With Appointment of Two Leading Medical Oncologists
Adlai Nortye has expanded its Scientific Advisory Board by appointing two eminent medical oncologists, Dr. Andrew Zelenetz and Dr. Jiaxin Niu. This strategic move aims to strengthen the company's clinical development and scientific innovation, particularly in oncology. The new ad
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 13 Jul 2026 13:41
- Source
- Moomoo
Market source
Industry context
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 13 Jul 2026 12:30
- Source
- Market source
Investing.com Canada
Direct company coverage
Adlai Nortye expands scientific advisory board with two oncologists By Investing.com
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 13 Jul 2026 11:31
- Source
- Investing.com Canada
Quiver Quantitative
Direct company coverage
Adlai Nortye Expands Scientific Advisory Board with Appointments of Dr. David S. Hong and Dr. Piro Lito
Adlai Nortye Ltd., a clinical-stage biotechnology company, announced the expansion of its Scientific Advisory Board with the appointments of Dr. David S. Hong and Dr. Piro Lito. These additions aim to enhance the company's oncology expertise, particularly in advancing its RAS inh
- Tone
- Positive 69/100
- Event
- Market update
- Published
- 13 Jul 2026 11:11
- Source
- Quiver Quantitative
Stock Titan
Direct company coverage
Two cancer drug specialists join Adlai Nortye’s science board
Adlai Nortye (NASDAQ: ANL), a clinical-stage biotechnology company, has expanded its Scientific Advisory Board by appointing leading medical oncologists Dr. David S. Hong and Dr. Piro Lito. These additions aim to strengthen the company's R&D strategy and clinical development, par
- Tone
- Positive 72/100
- Event
- Market update
- Published
- 13 Jul 2026 11:10
- Source
- Stock Titan
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – SWB:N2U0
This page from TradingView provides financial data for Adlai Nortye Ltd. Sponsored ADR (SWB:N2U0), specifically focusing on its enterprise value to EBITDA forward metric. The content highlights various functionalities and tools offered by TradingView, such as charting libraries,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 09 Jul 2026 12:17
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Adlai Nortye Ltd. – NASDAQ:ANL
This article focuses on the enterprise value to EBIT forward metric for Adlai Nortye Ltd., traded on NASDAQ under the symbol ANL. It appears to be a financial data point presented by TradingView, indicating a specific financial ratio for the company. The content itself seems to b
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 29 Jun 2026 15:11
- Source
- TradingView
TradingView
Direct company coverage
Price to sales forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0
The article focuses on the "Price to sales forward" financial metric for Adlai Nortye Ltd. Sponsored ADR, traded on the Frankfurt Stock Exchange under the symbol N2U0. It indicates that the market was closed with no trades when the data was accessed. The content is primarily a da
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 19:40
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBIT forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0
This article provides financial data on the Enterprise Value to EBIT forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0) on the Frankfurt Stock Exchange. It indicates the market status as closed with no trades. The content primarily serves as a financial data point within a la
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 10:37
- Source
- TradingView
TradingView
Direct company coverage
Price to book forward of Adlai Nortye Ltd. – NASDAQ:ANL
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 27 Jun 2026 09:20
- Source
- TradingView
TradingView
Direct company coverage
Number of shareholders of Adlai Nortye Ltd. – NASDAQ:ANL
This article provides details on the number of shareholders for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a financial data point showing the value and percentage change for the number of shareholders over a certain period, attributed to human analysis. The page is sourced from
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 23:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to EBITDA forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0
This article focuses on the enterprise value to EBITDA forward for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0), a company listed on the Frankfurt Stock Exchange. It provides financial data related to this metric, indicating its current value and any changes. The content appears to
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 26 Jun 2026 08:40
- Source
- TradingView
TradingView
Direct company coverage
Adlai Nortye Ltd. Sponsored ADR Actuals & Estimates (NASDAQ:ANL)
This article provides an overview of Adlai Nortye Ltd. (NASDAQ: ANL) actuals and estimates, detailing available financial data and analyst estimates. It highlights resources for exploring reported financial data, comparing actual results with estimates, and visualizing trends ove
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 25 Jun 2026 18:39
- Source
- TradingView
TradingView
Direct company coverage
ANL Forecast — Price Target — Prediction for 2027
This page provides forecast information for Adlai Nortye Ltd. (ANL) on the Nasdaq Stock Market. It indicates a current price target of 28.50 based on 6 analysts' 1-year forecasts, though specific max and min estimates are not provided. The content also includes sections for actua
- Tone
- Neutral 50/100
- Event
- Guidance
- Published
- 25 Jun 2026 14:11
- Source
- TradingView
TradingView
Direct company coverage
Price to earnings forward of Adlai Nortye Ltd. – NASDAQ:ANL
This article displays the future price-to-earnings ratio for Adlai Nortye Ltd. (NASDAQ: ANL). It presents a specific numerical value for this financial metric over a designated period, indicating its change and percentage change. The content appears to be a snapshot from a financ
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 24 Jun 2026 16:41
- Source
- TradingView
TradingView
Direct company coverage
Enterprise value to revenue forward of Adlai Nortye Ltd. Sponsored ADR – FWB:N2U0
This article focuses on the enterprise value to revenue forward metric for Adlai Nortye Ltd. Sponsored ADR (FWB:N2U0). It highlights the company's financial data available on TradingView, serving as a financial snapshot for potential investors or analysts.
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 24 Jun 2026 13:41
- Source
- TradingView
Intellectia AI
Direct company coverage
ANL Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of Adlai Nortye Ltd (ANL), detailing its revenue breakdown, profitability margins, and a comparison with its competitors. ANL reports a gross margin of 100.00% but negative operating and net margins, indicating challenges in converting o
- Tone
- Negative 35/100
- Event
- Earnings
- Published
- 24 Jun 2026 08:09
- Source
- Intellectia AI
Investing.com
Direct company coverage
Cantor Fitzgerald initiates Adlai Nortye stock with overweight rating
Cantor Fitzgerald initiated coverage on Adlai Nortye Ltd. (NASDAQ: ANL) with an overweight rating and a price target of $28 per share, suggesting approximately 180% upside. The biotechnology company focuses on the RAS pathway, developing AN9025, a Phase 1 panRAS inhibitor. Adlai
- Tone
- Positive 74/100
- Event
- Analyst action
- Published
- 22 Jun 2026 11:09
- Source
- Investing.com
TradingKey
Direct company coverage
Adlai Nortye Ltd (ANL) Earnings Forecast: Future EPS & Revenue Growth Estimates
The article provides an earnings forecast for Adlai Nortye Ltd (ANL), highlighting analyst ratings, target prices, and a peer comparison. Based on five analysts, the stock has a "Buy" trend with a target price of USD 9.00, suggesting a potential upside. Key financial metrics like
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 18 Jun 2026 05:10
- Source
- TradingKey
TradingKey
Direct company coverage
Adlai Nortye Ltd (ANL) Institutional Confidence
This article provides details on the institutional confidence in Adlai Nortye Ltd (ANL), including its current stock price, market capitalization, and institutional shareholding data. It lists key institutional shareholders and their share movements, with UBS Financial Services,
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 18 Jun 2026 05:10
- Source
- TradingKey
TradingKey
Direct company coverage
Adlai Nortye Ltd (ANL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
The article discusses the revenue breakdown of Adlai Nortye Ltd (ANL) by business segments and regional contributions. However, it states that relevant data for these breakdowns have not yet been disclosed by the company. The page provides general stock information for ANL, inclu
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 17 Jun 2026 20:09
- Source
- TradingKey
TradingKey
Direct company coverage
Adlai Nortye Ltd (ANL) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Adlai Nortye Ltd (ANL)'s dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and reports "No Data" for both historical dividend payments and stock splits, indicating a lack o
- Tone
- Neutral 50/100
- Event
- Capital return
- Published
- 17 Jun 2026 20:09
- Source
- TradingKey
Stock Titan
Direct company coverage
[Form 4] Adlai Nortye Ltd. Insider Trading Activity
This article details an insider trading activity for Adlai Nortye Ltd. (ANL) reported on a Form 4 filing. The transaction involves Ji Ping, a director, receiving 136,667 American Depository Shares, which were distributed from a trust, rather than being purchased. The filing indic
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 10 Jun 2026 16:10
- Source
- Stock Titan
Moomoo
Direct company coverage
H.C. Wainwright Maintains Adlai Nortye(ANL.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright has reiterated its Buy rating for Adlai Nortye (ANL.US) and maintained a target price of $20. This indicates the firm's continued positive outlook on the company's stock.
- Tone
- Positive 70/100
- Event
- Analyst action
- Published
- 10 Jun 2026 01:38
- Source
- Moomoo
Intellectia AI
Direct company coverage
ANL Should I Buy
This article analyzes whether Adlai Nortye Ltd (ANL) is a good investment, concluding it's a "Buy" for long-term investors based on strong analyst support and a promising pipeline, particularly its highly differentiated RAS-targeted programs. While there's no technical or options
- Tone
- Positive 73/100
- Event
- Analyst action
- Published
- 05 Jun 2026 23:09
- Source
- Intellectia AI
Quartr
Direct company coverage
Adlai Nortye (ANL) Jefferies Global Healthcare Conference 2026 Summary
The article summarizes Adlai Nortye's (ANL) presentation at the Jefferies Global Healthcare Conference 2026, highlighting key pipeline developments for its pan-RAS inhibitor AN9025, CEACAM5-targeting ADC AN4035, and next-generation IO program A025. It details scientific insights
- Tone
- Positive 74/100
- Event
- Market update
- Published
- 04 Jun 2026 15:10
- Source
- Quartr
Finviz
Direct company coverage
ANL - Adlai Nortye Ltd ADR Stock Price and Quote
This page provides a detailed stock quote and financial overview for Adlai Nortye Ltd ADR (ANL), a clinical-stage biopharmaceutical company focusing on cancer therapies. It includes real-time stock performance, key financial metrics, insider transaction data, analyst ratings, and
- Tone
- Negative 38/100
- Event
- Analyst action
- Published
- 03 Jun 2026 09:40
- Source
- Finviz